Sera Labs offers 1,500 recombinant proteins

Published: 1-Jun-2010
Research & Development

Including cytokines, growth factors, chemokines, hormones, enzymes and viral antigens

Sera Laboratories International, a UK-based serum specialist, has developed more than 1,500 recombinant proteins for a variety of species including human, mouse, rat, porcine, bovine and chicken. The collection includes cytokines, growth factors, chemokines, hormones, enzymes and viral antigens.

Sera Lab’s recombinant proteins are mainly derived from bacterial systems and also include mammalian, yeast, insect and plant sources. All are rigorously tested to ensure excellent quality and biological activity.

With headquarters and storage in Haywards Heath, West Sussex and a cell culture research facility in France, Sera Lab offers a complete range of animal-based research products from a variety of origins. The company supplies laboratories in more than 30 countries worldwide, either directly or through distributors.

See more

You may also like

Regulatory

TurboFil debuts latest generation of through-the-tip benchtop syringe filler

Read more
TipFil Plus provides precise, aseptic-ready filling and capping for lab and pharmacy applications

Trending Articles

  1. From powder to granules: a deep dive into wet granulation methods - WEBINAR NOW ON DEMAND Join ACG in partnership with Manufacturing Chemist for an expert-led session to explore how different wet granulation methods impact consistency, yield, and quality — and what really matters when it comes to selecting and optimising your process
  2. Orphan drug sales to exceed $400bn by 2032, Evaluate report finds Despite FDA policy shifts and the rise of blockbuster obesity drugs, a new Evaluate report confirms rare disease therapies are on track to claim more than a fifth of all global prescription drug sales within a decade
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258 The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists
  4. Why weight sorting should move earlier in OSD development Phillip Ruda explains how earlier weight intelligence can improve process understanding, reduce risk and accelerate learning cycles
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Moving with speed and scale: innovative, material-sparing approaches to accelerate clinical development As early-stage drug development is often hindered by limited API supply, rising costs and tight timelines, material-sparing technologies are helping companies to progress faster with less

Upcoming event

Cleanroom Technology Awards 2026

13 April | Virtual See all

You may also like

Regulatory

TurboFil debuts latest generation of through-the-tip benchtop syringe filler

TipFil Plus provides precise, aseptic-ready filling and capping for lab and pharmacy applications
Manufacturing

Concentrating recombinant proteins for drug discovery using centrifugal evaporation

Exploring purification, concentration and sample protection in recombinant protein workflows
Research & Development

COVID-19 immunity lowers the risk of a new pandemic

Researchers at the MRC-University of Glasgow Centre for Virus Research have demonstrated that the likelihood of the emergence of a new SARS-type virus pandemic has been significantly reduced by population-wide immunity to SARS-CoV-2
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Cytiva enters research partnership with SRTIGET for next-gen genomic medicine

The pair aim to expand the role of lipid nanoparticle technology into gene therapy delivery, including applications in cancer and inherited blood diseases, CNS delivery for neurological disorders where current methods fail and in vivo stem cell modification that could eliminate toxic conditioning regimens
Research & Development

Shimadzu’s Design Craftech

Fusing traditional Kyoto craft techniques with industrial production
Research & Development

Just – Evotec Biologics wins BARDA contract to optimise antibody biomanufacturing against Ebola and Sudan virus

Just – Evotec Biologics has been selected by BARDA to develop scalable, high-yield manufacturing processes for a monoclonal antibody cocktail targeting filovirus diseases under a multi-year programme valued at up to $10m
Research & Development

ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology

Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents
Subscribe now